Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.
Metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa) is a cause of life-threatening infections. With parenteral colistin not available in Japan, we treated MDR P. aeruginosa sepsis with monobactam and aminoglycoside combination therapy, with screening using a 'break-point checkerboard plate'.
Araoka
Hideki
H
Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan.
Baba
Masaru
M
Takagi
Shinsuke
S
Matsuno
Naofumi
N
Ishiwata
Kazuya
K
Nakano
Nobuaki
N
Tsuji
Masanori
M
Yamamoto
Hisashi
H
Seo
Sachiko
S
Asano-Mori
Yuki
Y
Uchida
Naoyuki
N
Masuoka
Kazuhiro
K
Wake
Atsushi
A
Taniguchi
Shuichi
S
Yoneyama
Akiko
A
D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008875:Middle Aged; D008997:Monobactams / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000096:biosynthesis*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D008997:Monobactams; D001618:beta-Lactamases